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STAT2 signaling restricts viral dissemination but
drives severe pneumonia in SARS-CoV-2 infected
hamsters
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Emergence of SARS-CoV-2 causing COVID-19 has resulted in hundreds of thousands of
deaths. In search for key targets of effective therapeutics, robust animal models mimicking
COVID-19 in humans are urgently needed. Here, we show that Syrian hamsters, in contrast to
mice, are highly permissive to SARS-CoV-2 and develop bronchopneumonia and strong
inflammatory responses in the lungs with neutrophil infiltration and edema, further confirmed
as consolidations visualized by micro-CT alike in clinical practice. Moreover, we identify an
exuberant innate immune response as key player in pathogenesis, in which STAT2 signaling
plays a dual role, driving severe lung injury on the one hand, yet restricting systemic virus
dissemination on the other. Our results reveal the importance of STAT2-dependent interferon
responses in the pathogenesis and virus control during SARS-CoV-2 infection and may help
rationalizing new strategies for the treatment of COVID-19 patients.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the family of Coronaviridae, whichcontains a large group of viruses that are constantly circu-
lating in animals and humans. Illness in humans caused by cor-
onaviruses is mostly mild and manifested by respiratory or
digestive problems as leading symptoms1. However, some cor-
onaviruses, such as SARS-CoV-1, Middle East respiratory
syndrome-related coronavirus (MERS-CoV) and the recent
SARS-CoV-2, have been responsible for serious outbreaks of
severe and lethal respiratory disease2,3. Unlike the previous out-
breaks with SARS-CoV-1 and MERS-CoV, the current SARS-
CoV-2 outbreak has evolved as the largest global health threat to
humanity in this century.
The unprecedented scale and rapidity of the current pandemic
urges the development of efficient vaccines and antiviral and anti-
inflammatory drugs. A key requisite in expediting this process are
animal models that recapitulate and allow to understand viral
pathogenesis. Such models can, hence, be used to identify new
drug targets and to rationalize and preclinically assess preventive
and therapeutic countermeasures.
Acute respiratory disease caused by SARS-CoV-1 and MERS
infections is characterized by a dysregulated inflammatory
response in which a delayed type I interferon (IFN) response
promotes the accumulation of inflammatory monocyte macro-
phages4–6. The severe lung disease in coronavirus disease 2019
(COVID-19) patients seems to result from a similar overshooting
inflammatory response2,7,8. However, because even non-human
primates do not fully replicate COVID-199, fragmentary infor-
mation and still no appropriate animal models, though urgently
sought, are currently available to address this hypothesis.
In this study, we set out to understand SARS-CoV-2-induced
pathogenesis by comparing SARS-CoV-2 infection in mice and
hamsters, including in animals with a knockout (KO) in key
components of adaptive and innate immunity. We show that
mice are barely susceptible to SARS-CoV-2 infection and that
viral replication in the lungs of mice is further restricted by type I
IFN signaling. We demonstrate that, in contrast to mice, Syrian
hamsters are highly permissive to SARS-CoV-2 infection and
virus-induced lung pathology. We establish that in hamsters a
dysregulated innate immune response is a driving force behind
SARS-CoV-2 pathogenesis, in which in particular signal trans-
ducer and activator of transcription factor 2 (STAT2)-dependent
type I and III IFN signaling plays a dual role: (i) restricting
infection and dissemination on one hand but (ii) driving devel-
opment of severe lung disease on the other.
Results
Type I IFN restrict SARS-CoV-2 infection in mice. To address
the lack of appropriate animal models, we first compared the
effect of SARS-CoV-2 infection in wild-type (WT) mice of dif-
ferent lineages (BALB/c and C57BL/6) and matched transgenic
mouse strains with a KO of key components of adaptive and
innate immunity. We used an original patient isolate of SARS-
CoV-2 (BetaCoV/Belgium/GHB-03021/2020; Supplementary
Fig. 1a), passaged on HuH7 and Vero E6 cells and fully char-
acterized by deep sequencing. No adventitious agents could be
detected (Supplementary Fig. 1b, c). SARS-CoV-2 virus stocks
from cell culture passage 4 (P4) and P6 were used.
To examine whether adaptive immunity contributed to the
susceptibility to SARS-CoV-2 infection, we inoculated WT
(immune-competent) and SCID mice (lacking functional T and
B cells) from the same BALB/c background intranasally with a
high 2 × 105 TCID50 (50% tissue culture infectious dose) viral
dose (P4 virus) (Fig. 1a). On day 3 post inoculation (p.i.), a viral
RNA peak in the lungs was observed (Fig. 1b and Supplementary
Fig. 2) with no obvious differences in viral loads (Fig. 1b) or lung
pathology (Fig. 1d and Supplementary Fig. 3a, b) between WT
and SCID mice. These data indicate that mice that lack the
human angiotensin-converting enzyme 2 (ACE2) receptor10 can
in principle be infected with SARS-CoV-2, although inefficiently
and likely transiently, as also observed for SARS-CoV-14,11.
However, adaptive immunity did not markedly contribute to this
low susceptibility.
IFNs are the prototypic first-line innate immune defense
against viral infections. For many respiratory viruses, including
SARS-CoV-1, in particular type I and III IFN signaling has been
described to play an important role in restricting infection
in vivo12. To evaluate the role of IFNs in SARS-CoV-2 infection,
we compared viral RNA levels and lung pathology in WT C57BL/
6 mice and C57BL/6 mice with a genetic ablation of their type I
(Ifnar1−/−) and III IFN receptors (Il28r−/−) (Fig. 1a). Ifnar1−/−
mice showed an enhanced replication of SARS-CoV-2 in the lung
on day 3 p.i. compared to both WT and Il28r−/− mice and heat-
inactivated inoculum (Fig. 1c). Similar to BALB/c mice, overall
viral loads were low with some evidence for an active, although
inefficient, virus replication in Ifnar1−/− mice. In general, mice of
all tested strains hardly supported SARS-CoV-2 lung infection,
with type I IFN signaling restricting viral replication in vivo.
WT and KO (Ifnar1−/−, Il28r−/−) mouse strains, all on
C57BL/6 background, presented consistently with only a mild
lung pathology. However, Ifnar1−/− mice showed increased levels
of intra-alveolar hemorrhage, sometimes accompanied by some
peri-bronchial inflammation (Fig. 1d and Supplementary Fig. 3a,
b). Further evidence for true infection and hence viral replication
was provided by transcriptomic analysis13 of infected lung tissues
(Fig. 1e and Supplementary Fig. 4), revealing (i) a correlation
between nucleic acid sensors TLR3/TLR9/DDX58/POLR3A and
viral load (Supplementary Fig. 4, Cluster 2), (ii) an upregulation
of classical antiviral effector molecules14 (enrichment P < 0.001)
such as cGAS, Mx1, IFIH1/MDA-5, IRF3, OAS1, OAS3, and PKR/
EIF2AK2 (Supplementary Fig. 4, Cluster 1), and (iii) down-
regulation of upstream regulators STAT1, STAT3, and
STING/TMEM173 (Supplementary Fig. 4, Cluster 3), in agree-
ment with a possible role for apoptosis15–17. In summary, our
data are in line with restriction of SARS-CoV-2 infection by the
IFN system in mice, as well as suggest limited inflammatory
responses in the lungs of mice, in contrast to COVID-19 in
humans18. Taken together, mice were considered as a poor model
to study COVID-19 pathogenesis or to assess the efficacy of
vaccines and treatments.
STAT2 signaling restricts SARS-CoV-2 replication in ham-
sters. In contrast to mice, Syrian hamsters have been reported to be
highly susceptible to SARS-CoV-119 and SARS-CoV-220–22 infec-
tion and might thus provide a useful small animal model to study
the involvement of immune responses in restricting SARS-CoV-2
infection and on SARS‑CoV-2-induced lung disease. Intranasal
inoculation of SARS-CoV-2 in WT hamsters resulted indeed
consistently in high viral RNA loads (Fig. 2b), a proxy used for the
quantification of viral loads in the lungs (Supplementary Fig. 5),
i.e., roughly 3–4 Log10 higher than in Ifnar1−/− mice (Fig. 1c), as
well as high infectious titers (Fig. 2c). Pretreatment with a neu-
tralizing SARS-CoV-1 and SARS-CoV-2-specific single-domain
antibody Fc fusion construct (VHH-72-Fc)23 reduced viral loads
~105-fold in the lung of WT hamsters, further confirming an active
and efficient virus replication and validating hamsters for testing of
therapeutic interventions (Fig. 2f). Little, if any, viral RNA was
detectable in the blood (Fig. 2d), spleen, upper small intestine, and
liver of infected WT hamsters (Fig. 2e).
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In order to investigate the roles of type I and III IFN during
SARS-CoV-2 infection and pathogenesis, we compared virus
replication levels in different tissues of WT hamsters and
hamsters with ablated STAT2 (STAT2−/− lacking type I and III
IFN signaling)24,25 and IL28R expression (IL28R-a−/− lacking
type III IFN signaling) (Fig. 2a). Alike in WT hamsters, no signs
of overt disease were recognized. Also, no marked differences
were observed in viral RNA levels in the lung of WT, STAT2−/−,
or IL28R-a−/− hamsters (Fig. 2b). However, in contrast to WT
hamsters, STAT2−/− hamsters had significantly higher titers of
infectious virus in the lung (~50-fold; Fig. 2c), along with very
high levels of viral RNA detectable in blood (Fig. 2d), spleen, liver,
and their upper and lower gastrointestinal tract26 (Fig. 2e).
Together, these data suggest that STAT2 is critical for keeping
virus replication and production of infectious progeny in the
lungs down, as well as for restricting systemic SARS-CoV-2
spread and suppressing viral replication outside of the lung
compartment. In line with a strong antiviral activity of STAT2 in
hamsters in vivo, a similar effect was also observed in human
Calu-3 cells in vitro where pharmacological inhibition of Janus-
activated kinase (Jak)/STAT signaling by Ruxolitinib27,28 could
fully rescue virus replication from the strong inhibitory activity of
type I IFN (Fig. 2g and Supplementary Fig. 6), further under-
scoring the role of STAT2 in controlling virus replication,
including in the human model.
STAT2 signaling drives SARS-CoV-2-induced lung disease.
Next, we used these different KO hamsters to evaluate the effect
of SARS-CoV-2 immune responses on lung pathology. In infected
WT hamsters, a marked lung pathology characterized by an
infiltration of polymorphonuclear leukocytes, bronchopneumo-
nia, and edema was observed (Fig. 3a and Supplementary Fig. 7).
This resembles histopathological findings in humans suffering
from severe COVID-19 bronchopneumonia29. Inversely, the
observed lung pathology was much attenuated in STAT2−/−
hamsters (Fig. 3a). On the contrary, IL28R-a−/− hamsters showed
clear signs of bronchopneumonia and peri-bronchiolar inflam-
mation, similar to those observed in WT animals (Fig. 3a). In
b
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Fig. 1 Type I interferon signaling restricts SARS-CoV-2 infection of the lungs of mice. a Schematic representation of SARS-CoV-2 inoculation schedule.
Several wild-type (WT) and knockout mouse strains were inoculated intranasally with 2 × 105 TCID50 of passage 4 (P4) SARS-CoV-2. On the indicated
days post inoculation (p.i.), lungs were collected for determination of viral RNA levels and scored for lung damage. b, c Normalized viral RNA levels in the
lungs of BALB/c WT (blue circles, n= 3) and SCID (red circles, n= 3) mice and C57BL/6 WT (blue circles, n= 5), Ifnar1−/− (day 2 p.i. (red circles, n= 3),
day 3 p.i. (red circles, n= 8), day 3 p.i. inactivated SARS-CoV-2 (red triangles, n= 4), day 4 p.i. (red circles, n= 3)), and Il28r−/− (purple circles, n= 5)
mice. At the indicated time intervals p.i., viral RNA levels were determined by RT-qPCR, normalized against β-actin mRNA levels and transformed to
estimate viral genome equivalents (vge) content per weight of the lungs (Supplementary Fig. 2). For heat inactivation, SARS-CoV-2 was incubated for 30
min at 56 °C. Dotted line indicates lower limit of quantification (LLOQ). The data shown are means ± SEM. d Histopathological scoring of the lungs for all
different mouse strains. Mice were sacrificed on day 3 p.i., and the lungs were stained with H&E and scored for signs of lung damage (inflammation and
hemorrhage). Scores are calculated as percentage of the total maximal score. “No score” means not contributing to theoretical full cumulative score of
100%. Numbers (n) of animals analyzed per condition are given in the inner circle. e Heatmap showing gene expression profiles of 30 selected marker
genes in the lungs of uninfected and infected Ifnar1−/− mice (n= 3 per group). Analysis performed on day 3 p.i. The scale represents fold change compared
to non-infected animals. Statistical significance between groups was calculated by two-tailed Mann–Whitney U test (b) or by Kruskal–Wallis with two-
sided Dunn’s post hoc test (c). P values: **P= 0.0013, *P= 0.035 (c); ns not significant.
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general, matching severity of lung pathology with the respective
viral loads in the lungs (Fig. 3b) reveals an obvious link between
infection and disease for WT and IL28R-a−/− hamsters, despite
variability in individual severity scores. Much by contrast, this
link is disrupted conjointly with the ablation of type I IFN
responses downstream of STAT2 signaling, in face of unrestricted
virus replication.
A similar picture is unveiled when assessing lung pathology by
computed tomography (CT). CT imaging was established here by
the lack of readily accessible serum markers and absence of overt
disease symptoms as a non-invasive means to score for SARS-
CoV-2-induced lung disease, alike in standard patient care to aid
COVID-19 diagnosis with high sensitivity and monitor progres-
sion/recovery7,8,30,31. Similar as in humans32, semi-quantitative
lung pathology scores were obtained from high-resolution chest
micro-CT scans of free-breathing animals33. Pulmonary con-
solidations were present in SARS-CoV-2-infected WT and IL28R-
a−/− hamsters but not in STAT2−/− hamsters (Fig. 3c and
Supplementary Fig. 8). Apart from lung consolidations and
airway dilation as main observed pathology, marked differences
in other micro-CT-derived markers of specific lung pathology,
such as hyperinflation, emphysema, or atelectasis34,35, were not
observed, except in one animal that presented with hyperinflation
(Supplementary Fig. 8c). Again, STAT2−/− hamsters showed
minimal lung involvement (Fig. 3c). Further quantitative
analysis34 revealed an increase of the non-aerated lung volume
in SARS-CoV-2-infected WT and IL28R-a−/− hamsters, yet again
not in STAT2−/− hamsters (Fig. 3d and Supplementary Fig. 8e).
First, these data fully support micro-CT as a convenient adjunct
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Fig. 2 Type I and III interferon signaling restricts SARS-CoV-2 replication in hamsters. a Schematic representation of SARS-CoV-2 inoculation schedule.
WT (blue), STAT2−/− (red), and IL28R-a−/− (purple) hamster strains were inoculated intranasally with 2 × 105 TCID50 of passage 4 or 2 × 106 of passage
6 SARS-CoV-2. Outcomes derived from inoculation with passage 4 or passage 6 SARS-CoV-2 is designated by circles (P4, n= 3) or squares (P6, n= 4).
On the indicated days post inoculation (p.i.), organs and blood were collected to determine viral RNA levels and infectious viral load. Viral loads in the
indicated organs were quantified by RT-qPCR (b, d–f) or virus titration (c). b, e Viral RNA levels in the lungs (day 2 and day 3 p.i. of each genotype (n= 3);
day 4 p.i. of each genotype (n= 7)) (b) or the indicated organs on day 4 p.i. (n= 4 for each genotype) (e) were normalized against β-actin mRNA levels
and transformed to estimate viral genome equivalents (vge) content per weight of the tissue (Fig. S5). c Infectious viral loads in the lung on day 4 p.i. are
expressed as the number of infectious virus particles per 100mg of lung tissue (n= 7 for each genotype). d Viral RNA levels in the blood (day 2 and day 3
p.i. of each genotype (n= 3); day 4 p.i. of each genotype (n= 7)) were calculated from a standard of infectious virus and expressed as TCID50 equivalents
per ml blood. Dotted lines indicate lower limit of quantification (LLOQ) or lower limit of detection (LLOD). f Viral RNA levels in hamsters after treatment
with a previously described single-domain antibody. Hamsters were either left untreated (blue, n= 5) or treated with VHH-72-Fc (green, n= 4) and
sacrificed on day 4 p.i. Viral RNA levels were determined in the lungs, normalized against β-actin, and fold changes were calculated using the 2(−ΔΔCq)
method compared to the mean of untreated control. g Inhibition of JAK/STAT signaling by Ruxolitinib can rescue SARS-CoV-2 virus replication in human
airway epithelial cells from the antiviral effect of type I IFN. Calu-3 (human airway epithelial) cells were left untreated or treated with Ruxolitinib (4 µM),
IFN-α (10 IU/ml), or a combination of both (n= 8 for each condition). Treatment was initiated 4 h before infection and was continued through the whole
experiment. Cultures were infected with P6 SARS-CoV-2 (MOI of 0.1), and 48 h p.i., cell culture supernatant was collected, RNA was extracted, and the
amount of vRNA was quantified using RT-qPCR. A serial dilution of the same virus stock was used to generate a standard curve for absolute quantification.
The data shown are mean ± SEM. Statistical significance between groups was calculated by Kruskal–Wallis with two-sided Dunn’s post hoc test (b–d, g) or
by an unpaired two-sided t test (f). P values: *P= 0.010 (c), ***P= 0.0009 and *P= 0.02 (d), ****P < 0.0001 (f), *P= 0.022 and *P= 0.013 (left to right
in g); ns not significant.
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visualize and quantify SARS-CoV-2-induced lung injury in the
hamster model. Moreover, it may allow to monitor the impact of
therapeutic measures non-invasively during disease progression.
Second, of relevance for COVID-19 immunopathogenesis, virus
replication was unlinked from lung disease in STAT2−/−
hamsters (Supplementary Fig. 8f).
An elevation of serum levels of several cytokines such as
interleukin (IL)-6, IL-10, and IFN-γ is reported in critically ill
COVID-19 patients2,7,8. Intriguingly, these genes were also
induced in the lungs of infected hamsters (Fig. 3f, g and
Supplementary Fig. 9a), along with elevated mRNA levels of IP-
10 (CXCL-10) as reported for other cytokines/chemokines
downstream of IFN-γ20, and of MX-2 downstream of type I
and III IFNs. However, WT, STAT2−/−, and IL28R-a−/−
hamsters each showed marked differences in the respective
expression levels (Fig. 3f), with overall strongest induction in WT
hamsters. First of all, IFN-stimulated genes36 such as MX-2
(strongly induced by type I IFN/STAT2 signaling) and IP-10
(induced by both type I and type II IFNs) showed a differential
expression pattern when comparing the different genotypes,
triggered by SARS-CoV-2 infection. Lower baseline expression of
MX-2 and IP-10 and failure to respond to SARS-CoV-2 infection
by MX-2 upregulation in STAT2−/− hamsters confirmed the
functional KO (Supplementary Fig. 9a). As expected, IL28R-a−/−
hamsters showed an intermediate phenotype between that of WT
and STAT2−/− concerning their antiviral IFN response. Of note,
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the receptor KOs did not affect ACE2 expression37,38 in the
hamster lungs (Supplementary Fig. 9a). Importantly, the expres-
sion levels of IP-10 and MX-2, and to a lesser extent also of IL-6
(Fig. 3g, h; for other possible molecular markers, see Supple-
mentary Fig. 9b), correlated with the disease severities observed in
the respective hamster strains (Fig. 3a, c–e), with lowest
inflammatory and antiviral cytokine responses in the absence of
STAT2-dependent type I and III IFN signaling.
Discussion
For the development of efficient therapeutic interventions against
SARS-CoV-2, relevant small animal models are needed that
mimic the different clinical manifestations of COVID-19 and that
provide fundamental mechanistic insight into the underlying
pathology/pathogenesis. Transgenic mice expressing hACE2, the
bona fide receptor of SARS-CoV-1 and SARS-CoV-239, have been
suggested as COVID-19 model40–42. We here demonstrate that
WT mice are also susceptible to SARS-CoV-2 infection, yet
resulting in very limited viral replication and inflammatory
responses. Ablation of type I IFN signaling in Ifnar1−/− mice
results in the same small incremental 10-fold increase in viral
replication as was originally reported for SARS-CoV-139,43 in
hACE2 transgenic mice, though recent data suggest an approx-
imate 100-fold increase for SARS-CoV-2 in such models40,42.
Nevertheless, neither mouse model fully recapitulates pathogen-
esis of COVID-19 nor allows the study of clinical SARS-CoV-2
isolates without prior adaptation44. It remains of interest to
investigate the added effect of both (i) hACE2 knock-in, and (ii)
Ifnar and/or Il28r KO in mice12,45. In fact, in WT mice that had
been transduced using adenoviral vectors expressing hACE2 to
facilitate SARS-CoV-2 infection, concomitant blockage of IFNAR
by receptor-neutralizing antibodies resulted in enhanced
disease46.
In contrast to mice, SARS-CoV-2 infection and associated
pathology in WT hamsters seems to resemble what has been
reported for SARS-CoV-1 in the same model, confirmed in the
meantime also by others20–22. An early peak of active virus
replication was noted in the lungs with viremia and extra-
pulmonary spread. This was accompanied by a strong acute
inflammatory response19 (as visualized by histopathology) with
induction of IL-6, IL-10, and IFN-γ expression (albeit with some
variation between animals) like in humans2,7,8,47,48 and, as a
consequence, pulmonary damage that could readily be depicted as
tissue consolidations and obstruction of the lungs by chest micro-
CT as established in this study. Micro-CT may hence become a
key instrument to non-invasively and quantitatively monitor
SARS-CoV-2 lung disease. This will allow to conveniently
monitor the effect of therapeutic strategies and test the preclinical
efficacy of vaccine candidates.
In humans, SARS-CoV-2 infection begins frequently with a flu-
like illness, followed in a second phase by an intense inflamma-
tory response characterized by a cytokine storm and acute lung
injury (ALI) and respiratory distress syndrome (ARDS) asso-
ciated with high mortality2,7,8. Considering the very acute and
short-lived infection kinetics observed in intranasally inoculated
hamsters20,21 that may not allow for full development of pro-
tracted (bi-phasic) COVID-19-like disease22, we studied SARS-
CoV-2-induced pathology as early as 4 days p.i. Nevertheless,
main pathological findings seem to resemble to a large extent
what is observed in humans. Some variability in infection out-
come, in particular in pathology scores of WT hamsters (Fig. 3b,
h and Supplementary Fig. 8f), may be explained by two experi-
mental constraints. First, the genetics of WT hamsters that are
outbred and may hence show a varying susceptibility, as hypo-
thesized in humans27. Second, the use of SARS-CoV-2 stocks
from two passages P4 and P6 virus stocks. Sequencing analysis of
the virus stocks revealed two small in-frame deletions in Spike (S)
glycoprotein (i.e., in the N-terminal domain and the furin-
cleavage site49–51; Supplementary Fig. 1b, c) to dominate in the
P6 virus used, likely as a consequence of adaptation to enhanced
growth in Vero E6 cells in vitro. This observation is in line with
earlier reports, namely, of tissue culture-adaptive mutations
similar to those observed by us (Supplementary Fig. 1b, c)
resulting in reduced fitness of SARS-CoV-2 in WT hamsters (no
body weight loss and attenuation of pathology)52, emphasizing
possible consequences of using cell culture-adapted virus when
studying SARS-CoV-2 infection in animal models.
By using unique KO hamster lines, we demonstrated that
STAT2 plays a critical role in mediating antiviral responses and
restricting systemic dissemination of SARS-CoV-2 (see Fig. 3i for
a summary of phenotypes). This is in line with the effect of
STAT1 in a mouse model of SARS-CoV-1 infection53. However
and much in contrast to what is generally observed for viral
infections in Stat2−/− mice54 or STAT2−/− hamsters25,55,56, the
severe pathology induced by SARS-CoV-2 in WT hamsters is not
observed in the absence of STAT2. Indeed, pneumonia as
Fig. 3 Exuberant innate response by STAT2 drives SARS-CoV-2-induced lung pathology in hamsters. WT (blue), STAT2−/− (red), and IL28R-a−/−
(purple) hamster strains were inoculated intranasally with 2 × 105 TCID50 of passage 4 (circles, n= 3) or 2 × 106 of passage 6 (squares, n= 4) SARS-CoV-
2. On day 4 p.i., lungs and blood were collected to score for lung damage and determine gene expression levels. a Cumulative lung pathology scores for
signs of damage. Lungs were stained with H&E and scored for signs of inflammation, bronchopneumonia, edema, apoptotic bodies, and necrotizing
bronchiolitis (n= 7 for each genotype). b Matched comparison between infectious viral load in the lung (left Y-axis) (values from Fig. 2c) and
histopathological scores (right Y-axis) (values used in a). Lines indicate matched samples (n= 7 for each genotype). c–e Micro-CT to score for signs of
damage in infected (P6 SARS-CoV-2) WT (n= 4), STAT2−/− (n= 4), and IL28R-a−/− (n= 3) hamster lungs. c Representative transversal micro-CT
images. Yellow arrows indicate examples of pulmonary infiltrates seen as consolidation of lung parenchyma. d Five transverse cross-sections at different
positions in the lung were selected for each animal and scored to quantify lung consolidations. e Quantification of the micro-CT-derived non-aerated lung
volume biomarker, reflecting the volume of consolidations in the lungs. The data shown are mean ± SEM and lines indicate healthy animals (n= 3) (d, e). f,
g Heat map or individual expression profiles showing differential expression of selected antiviral, pro-inflammatory, and cytokine genes in the lungs after
SARS-CoV-2 infection (n= 7 per group) relative to non-infected genotype matched controls (WT (n= 7), STAT2−/− (n= 3), and IL28R-a−/− (n= 3)).
RNA levels were determined by RT-qPCR on lung extracts, normalized for β-actin mRNA levels, and fold changes over the median of uninfected controls
were calculated using the 2(−ΔΔCq) method. Only for IFN-λ, where all uninfected control animals had undetectable RNA levels, fold changes were
calculated over the lowest detectable value. Data presented as fold change (f) or log2 fold change over non-infected control (g) Bars represent median ±
IQR. h Correlation between histopathological scores (derived from Fig. 3a) and natural log-normalized gene expression levels (derived from Fig. 3f, g and
Supplementary Fig. 9) in uninfected and infected animals. Non-infected animals are indicated by triangles. i A spider-web plot showing lung pathology
scores (CT lung score, non-aerated lung volume, bronchopneumonia, and inflammation), cumulative gene expression level scores, and infectious virus
levels normalized to SARS-CoV-2-infected WT hamsters. Statistical significance between genotypes was calculated by Kruskal–Wallis with two-sided
Dunn’s post hoc test (d, e, g) and Spearman correlation (h). P values: **P= 0.0082 and **P= 0.0025 (left to right in g).
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assessed by sensitive micro-CT was absent in STAT2−/− ham-
sters. Considering the established negative regulation of IL-6 and
other mediators of inflammation by STAT254,57, our hamster
model may help to understand the immune pathogenesis of ALI
and ARDS caused by highly pathogenic coronaviruses12,19,58 as
well as other respiratory viruses4. Of note, a meta-analysis of
infected human cells revealed a specific SARS-CoV-2-regulated
transcriptional footprint for STAT2 in particular that was
stronger than that of any other inflammatory transcription
factor59.
The increase in replication of SARS-CoV-2 seen in IL28R-a−/−
hamsters, on one hand, combined with a tempered inflammatory
response and lung injury as compared to WT hamsters, on the
other hand, is in line with the role type III IFN plays during
respiratory virus infections, including in SARS-CoV-145. This
observation also suggests that in humans pegylated IFN-
lambda60,61 (or similar modulators of innate immunity) may
possibly be considered to protect medical staff and other frontline
workers from SARS-CoV-2 infection or to dampen symptoms in
critically ill patients62, however, with caution considering a
potential pathophysiological role of IFN-lambda63,64.
In conclusion, hamsters may be preferred above mice as
infection model for the preclinical assessment of antiviral thera-
pies, of vaccines, and of approaches that aim at tempering the
COVID-19 immune pathogenesis in critically ill patients18,65. The
latter may be achieved by repurposing anti-inflammatory drugs66
such as IL-6 receptor antagonists (e.g., Tocilizumab)67–70 or small
molecule Jak/STAT inhibitors (e.g., Ruxolitinib71,72 or Tofaciti-
nib). Educated by our finding that STAT2 signaling plays a dual
role in also limiting viral dissemination, targeting the virus-
induced cytokine response and overshooting of macrophage
activation may need to be complemented by (directly acting)
antivirals73.
Methods
Animals. WT Syrian hamsters (Mesocricetus auratus) were purchased from Janvier
Laboratories. All other mouse (C57BL/6, Ifnar1−/−, Il28r−/−, BALB/c, and SCID)
and hamster (STAT2−/− and IL28R-a−/−) strains were bred in-house. Six-to-8-
week-old female mice and female WT hamsters were used throughout the study.
KO hamsters were used upon availability: 7–12-week-old female STAT2−/−
hamsters and 5–7-week-old IL28R-a−/− hamsters.
Ifnar1−/− mouse breeding couples were a generous gift of Dr. Claude Libert,
IRC/VIB, University of Ghent, Belgium. Il28r−/− mice [C57B/6N-
A<tm1Brd>Ifnlr1<tm1a(EUCOMM)Wtsi>/Wtsi, strain ID: EM:07988] were
provided by the Wellcome Trust Sanger Institute Mouse Genetics Project (Sanger
MGP)74.
STAT2−/− and IL28R-a−/− hamsters were generated by CRISPR/Cas-mediated
gene targeting. To ablate STAT2 (Gene ID: 101830537) expression, a 1-nt
frameshift mutation was introduced in exon 4 resulting in multiple premature stop
codons24; to ablate IL28R (IFNLR1; Gene ID: 101833778) expression, a 22-
nucleotide deletion was introduced in exon 2 resulting in multiple premature stop
codons in the original open reading frame.
Animals were housed individually (hamsters) or per 5 (mice) in individually
ventilated isolator cages (IsoCage N Biocontainment System, Tecniplast) at a
temperature of 21 °C, humidity of 55%, and 12:12 dark/light cycles, with access to
food and water ad libitum, and cage enrichment (cotton and cardboard play
tunnels for mice, wood block for hamsters). Housing conditions and experimental
procedures were approved by the ethical committee of KU Leuven (license P015-
2020), following institutional guidelines approved by the Federation of European
Laboratory Animal Science Associations (FELASA). Animals were euthanized by
100 µl (mice) or 500 µl (hamsters) of intraperitoneally (i.p.) administered Dolethal
(200 mg/ml sodium pentobarbital, Vétoquinol SA). Animals were monitored daily
for signs of disease (lethargy, heavy breathing, or ruffled fur).
Prior to infection, the animals were anesthetized by i.p. injection of a xylazine
(16 mg/kg, XYL-M®, V.M.D.), ketamine (40 mg/kg, Nimatek, EuroVet), and
atropine (0.2 mg/kg, Sterop) solution. Each animal was inoculated intranasally by
gently adding 50 µl droplets of virus stock containing 2 × 105 TCID50 (P4 virus) or
2 × 106 TCID50 (P6 virus) in both nostrils. Uninfected animals did not receive any
virus or matrix. Due to time constraints by the pandemic outbreak and the urgency
to develop a small animal model, we have used virus stock from two different
passages (P4 and P6) to characterize our model. A full genotypic characterization
of the viruses used is provided in Supplementary Fig. 1, and phenotypic differences
and virus titers are provided in the text and legends.
Cells, virus, and sera. Vero E6 (African green monkey kidney, kind gift from
Peter Bredenbeek, LUMC, NL) and HuH7 (human hepatoma, JCRB0403) cells
were maintained in minimal essential medium (Gibco) supplemented with 10%
fetal bovine serum (Integro), 1% bicarbonate (Gibco), and 1% L-glutamine (Gibco).
For maintenance of Calu-3 cells (human airway epithelium, kind gift from Lieve
Naesens, KU Leuven, BE), the above medium was supplemented with 10 mM
HEPES (Gibco). All assays involving virus growth were performed using 2% (Vero
E6 and HuH7) or 0.2% (Calu-3) fetal bovine serum instead of 10%.
SARS-CoV-2 strain BetaCov/Belgium/GHB-03021/2020 (EPI ISL 407976|2020-
02-03) recovered from a nasopharyngeal swab taken from a reverse transcription
quantitative polymerase chain reaction (RT-qPCR)-confirmed asymptomatic
patient returning from Wuhan, China beginning of February 202075 was directly
sequenced on a MinION platform (Oxford Nanopore)76. Phylogenetic analysis
confirmed a close relation with the prototypic Wuhan-Hu-1 2019-nCoV (GenBank
accession number MN908947.3) strain. Infectious virus was isolated by serial
passaging on HuH7 and Vero E6 cells (see Supplementary Fig. 1), with the addition
of penicillin/streptomycin, gentamicin, and amphotericin B. Virus used for animal
experiments was from passages P4 and P6. Prior to inoculation of animals, virus
stocks were confirmed to be free of mycoplasma (PlasmoTest, InvivoGen) and
other adventitious agents by deep sequencing on a MiSeq platform (Illumina)
following an established metagenomics pipeline77,78. The infectious content of
virus stocks was determined by titration on Vero E6 cells by the Spearman–Kärber
method. All virus-related work was conducted in the high-containment BSL3+
facilities of the KU Leuven Rega Institute (3CAPS) under licenses AMV 30112018
SBB 219 2018 0892 and AMV 23102017 SBB 219 2017 0589 according to
institutional guidelines.
Antibody VHH-72-Fc was administered i.p. at a dose of 20 mg/kg 1 day prior to
infection. VHH-72-Fc was expressed in ExpiCHO cells (ThermoFisher Scientific)
and purified from the culture medium as described23. Briefly, after transfection
with pcDNA3.3-VHH-72-Fc plasmid DNA, followed by incubation at 32 °C and
5% CO2 for 6–7 days, the VHH-72-Fc protein in the cleared cell culture medium
was captured on a 5 ml MabSelect SuRe column (GE Healthcare), eluted with a
McIlvaine buffer pH 3, neutralized using a saturated Na3PO4 buffer, and buffer
exchanged to storage buffer (25 mM L-Histidine, 125 mM NaCl). The antibody’s
identity was verified by protein- and peptide-level mass spectrometry.
RNA extraction and RT-qPCR. Animals were euthanized at different time points
postinfection, organs were removed, and lungs were homogenized manually using
a pestle and a 12-fold excess of cell culture medium (Dulbecco’s modified Eagle’s
medium/2% fetal calf serum). RNA extraction was performed from homogenate of
30 mg of lung tissue with the RNeasy Mini Kit (Qiagen), or 50 µl of serum using the
NucleoSpin Kit (Macherey-Nagel), according to the manufacturer’s instructions.
Other organs were collected in RNALater (Qiagen) and homogenized in a bead
mill (Precellys) prior to extraction. Of 100 µl eluate, 4 µl was used as template in
RT-qPCR reactions. RT-qPCR was performed on a LightCycler96 platform
(Roche) using the iTaq Universal Probes One-Step RT-qPCR Kit (BioRad) with
primers and probes (Supplementary Table 1) specific for SARS-CoV-2, mouse β-
actin (Actb), and hamster β-actin (ACTB), IL6, IL10, IFNλ, IFNγ, MX2, IP-10,
TNFα, and ACE2 (IDT). SARS-CoV-2 qPCR reactions were carried out in dupli-
cate for each data point. Standards of SARS-CoV-2 cDNA (IDT) and infectious
virus were used to express the amount of RNA as normalized viral genome
equivalent copies per milligram tissue or as TCID50 equivalents per milliliter
serum, respectively. The mean of housekeeping gene β-actin was used for nor-
malization. The relative fold change was calculated using the 2−ΔΔCt method79.
Quantification of SARS-CoV-2 infectious particles in lung tissues. After
extensive transcardial perfusion with phosphate-buffered saline (PBS), lungs were
collected, extensively homogenized using manual disruption (Precellys24) in
minimal essential medium (5% w/v), and centrifuged (12,000 rpm, 10 min, 4 °C) to
pellet the cell debris. Infectious SARS-CoV-2 particles were quantified by means of
endpoint titrations on confluent Vero E6 cell cultures. Viral titers were calculated
by the Spearman–Kärber method and expressed as the TCID50 per 100 mg tissue.
Differential gene expression and bioinformatics analysis. To study differential
gene expression, RNA was extracted from lung tissues using Trizol, subjected to
cDNA synthesis (High Capacity cDNA Reverse Transcription Kit, Thermo Fisher
Scientific) and qPCR using a custom Taqman qRT-PCR array (Thermo Fisher
Scientific) of 30 genes known to be activated in response to virus infection13, as well
as two housekeeping genes (Supplementary Table 2). Data collected were analyzed
using the Quant Studio Design and Analysis (version 1.5.1) and Data Assist
software (version 3.01, Thermo Fisher Scientific). Pathway, Gene Ontology, and
transcription factor target enrichment analysis was performed using Gene Set
Enrichment Analysis (Molecular Signatures Database (MSigDB), Broad Institute).
Principal component analysis, correlation matrices, and unsupervised hierarchical
clustering (Euclidean distance) were performed using XLSTAT and visualized
using MORPHEUS (https://software.broadinstitute.org/morpheus)17.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19684-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5838 | https://doi.org/10.1038/s41467-020-19684-y | www.nature.com/naturecommunications 7
Histology. For histological examination, the lungs were fixed overnight in 4%
formaldehyde and embedded in paraffin. Tissue sections (4 µm) were stained with
hematoxylin and eosin to visualize and score for lung damage.
In vitro JAK/STAT inhibition assay. Calu-3 (human airway epithelial) cells were
plated at 5 × 104 cells/well in a 96-well plate and incubated overnight with 4 µM of
the JAK1/2 inhibitor Ruxolitinib80 (Toronto Research Chemicals, ON, Canada).
Next day, cells were pretreated for 4 h with 10 IU/ml of Universal type I IFN (PBL
Assay Science, NJ, USA, cat. no. 11200) before infection with SARS-CoV-2 (P4 or
P6, 5 × 103 TCID50 per well). Two hours post infection, cells were washed with PBS
and incubated for an additional 48 h with IFN and Ruxolitinib before collection of
the supernatant for RNA extraction and quantification of virus yields by RT-qPCR.
Micro-CT and image analysis. Hamsters were anesthetized using isoflurane (Iso-
Vet) (2–3% in oxygen) and installed in prone position into the X-cube micro-CT
scanner (Molecubes) using a dedicated imaging bed. Respiration was monitored
throughout. A scout view was acquired and the lung was selected for a non-gated,
helical CT acquisition using the High-Resolution CT protocol, with the following
parameters: 50 kVp, 960 exposures, 32 ms/projection, 350 µA tube current, rotation
time 120 s. Data were reconstructed using a regularized statistical (iterative) image
reconstruction algorithm using non-negative least squares81, using an isotropic
100 µm voxel size, and scaled to Hounsfield Units after calibration against a
standard air/water phantom. The spatial resolution of the reconstruction was
estimated at 200 µm by minimizing the mean squared error between the three-
dimensional reconstruction of the densest rod in a micro-CT multiple density rod
phantom (Smart Scientific) summed in the axial direction and a digital phantom
consisting of a two-dimensional disk of 17.5 mm radius that was post-smoothed
with Gaussian kernels using different full width half maxima, after aligning the
symmetry axis of the rod to the z-axis.
Visualization and quantification of reconstructed micro-CT data was performed
with DataViewer and CTan software (Bruker micro-CT). As primary outcome
parameter, a semi-quantitative scoring of micro-CT data was performed33,34,82
with minor modifications toward optimization for COVID-19 lung disease in
hamsters. In brief, visual observations were scored (from 0 to 2 depending on
severity, both for parenchymal and airway disease) on 5 different, predefined
transversal tomographic sections throughout the entire lung image for both lung
and airway disease by two independent observers (L.S. and G.V.V.) and averaged.
Scores for the 5 sections were summed up to obtain a score from 0 to 10 reflecting
severity of lung and airway abnormalities compared to scans of healthy, WT
control hamsters. As secondary measures, image-derived biomarkers (non-aerated
lung volume, aerated lung volume, total lung volume, the respective densities
within these volumes, and large airway volume) were quantified as in refs. 33,82 for
a manually delineated volume of interest in the lung, avoiding the heart and main
blood vessels. The threshold used to separate the airways and aerated (gray value
0–55) from non-aerated lung volume (gray value 56–255) was set manually on an
8-bit grayscale histogram and kept constant for all data sets.
Statistical analysis. GraphPad Prism Version 8 (GraphPad Software, Inc.) was
used for all statistical evaluations. The number of animals and independent
experiments that were performed is indicated in the legends to figures. Statistical
significance was determined using non-parametric Mann–Whitney U test for
pairwise comparisons or Kruskal–Wallis test with Dunn’s post hoc test for multiple
comparisons. Values were considered significantly different at P values of ≤0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
SARS-CoV-2 strain BetaCov/Belgium/GHB-03021/2020 sequence is available from
GISAID (EPI ISL 407976|2020-02-03, https://www.gisaid.org). Prototypic Wuhan-Hu-1
2019-nCoV sequence is available from GenBank (accession number MN908947.3). All
data supporting the findings in this study are also available from the corresponding
author upon request. Source data are provided with this paper.
Received: 18 September 2020; Accepted: 27 October 2020;
References
1. Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses.
Nat. Rev. Microbiol. 17, 181–192 (2019).
2. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China,
2019. N. Engl. J. Med. 382, 727–733 (2020).
3. Chen, J. et al. Clinical progression of patients with COVID-19 in Shanghai,
China. J. Infect. 80, e1 (2020).
4. Channappanavar, R. et al. Dysregulated type I interferon and inflammatory
monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-
infected mice. Cell Host Microbe 19, 181–193 (2016).
5. Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections:
causes and consequences of cytokine storm and immunopathology. Semin.
Immunopathol. 39, 529–539 (2017).
6. Page, C. et al. Induction of alternatively activated macrophages enhances
pathogenesis during severe acute respiratory syndrome coronavirus infection.
J. Virol. 86, 13334–13349 (2012).
7. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019
novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323,
1061–1069 (2020).
8. Huang, C. et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
9. Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in
a nonhuman primate model. Science 368, 1012–1015 (2020).
10. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell 181, 271.e8–280.
e8 (2020).
11. Ishii, K. et al. Neutralizing antibody against severe acute respiratory syndrome
(SARS)-coronavirus spike is highly effective for the protection of mice in the
murine SARS model. Microbiol. Immunol. 53, 75–82 (2009).
12. Mahlakõiv, T. et al. Combined action of type I and type III interferon restricts
initial replication of severe acute respiratory syndrome coronavirus in the
lung but fails to inhibit systemic virus spread. J. Gen. Virol. 93, 2601–2605
(2012).
13. Sharma, S. et al. Small molecule inhibitors of TBK1 serve as adjuvant for a
plasmid-launched live-attenuated yellow fever vaccine. Hum. Vaccines
Immunother. 16, 2196–2203 (2020).
14. Schoggins, J. W. Interferon-stimulated genes: what do they all do? Annu. Rev.
Virol. 6, 567–584 (2019).
15. Khouri, R. et al. A genetic IFN/STAT1/FAS axis determines CD4 T stem cell
memory levels and apoptosis in healthy controls and Adult T-cell Leukemia
patients. Oncoimmunology 7, e1426423 (2018).
16. Van Weyenbergh, J., Wietzerbin, J., Rouillard, D., Barral-Netto, M. & Liblau,
R. Treatment of multiple sclerosis patients with interferon-beta primes
monocyte-derived macrophages for apoptotic cell death. J. Leukoc. Biol. 70,
745–748 (2001).
17. Delgobo, M. et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to
monocyte expansion and tuberculosis severity in humans. Elife 8, e47013
(2019).
18. Zumla, A., Hui, D. S., Azhar, E. I., Memish, Z. A. & Maeurer, M. Reducing
mortality from 2019-nCoV: host-directed therapies should be an option.
Lancet 395, e35–e36 (2020).
19. Roberts, A. et al. Severe acute respiratory syndrome coronavirus infection of
golden Syrian hamsters. J. Virol. 79, 503–511 (2005).
20. Chan, J. F.-W. et al. Simulation of the clinical and pathological manifestations
of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model:
implications for disease pathogenesis and transmissibility. Clin. Infect. Dis.
https://doi.org/10.1093/cid/ciaa325 (2020).
21. Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden
hamsters. Nature 583, 834–838 (2020).
22. Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2
infection and countermeasure development. Proc. Natl Acad. Sci. USA 117,
16587–16595 (2020).
23. Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses
by single-domain camelid antibodies. Cell 181, 1436–1441 (2020).
24. Fan, Z. et al. Efficient gene targeting in golden Syrian hamsters by the
CRISPR/Cas9 system. PLoS ONE 9, e109755 (2014).
25. Toth, K. et al. STAT2 knockout Syrian hamsters support enhanced replication
and pathogenicity of human adenovirus, revealing an important role of type I
interferon response in viral control. PLoS Pathog. 11, e1005084 (2015).
26. Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2
infection. Gut 69, 997–1001 (2020).
27. Bagca, B. G. & Avci, C. B. The potential of JAK/STAT pathway inhibition by
ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev. 54,
51–61 (2020).
28. Felgenhauer, U. et al. Inhibition of SARS-CoV-2 by type I and type III
interferons. J. Biol. Chem. 295, 13958–13964 (2020).
29. Xu, Z. et al. Pathological findings of COVID-19 associated with acute
respiratory distress syndrome. Lancet Respir. Med. 8, 420–422 (2020).
30. Ai, T. et al. Correlation of chest CT and RT-PCR testing in coronavirus
disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 296,
E32–E40 (2020).
31. Chen, T. et al. Clinical characteristics of 113 deceased patients with
coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).
32. Shi, H. et al. Radiological findings from 81 patients with COVID-19
pneumonia in Wuhan, China: a descriptive study. Lancet Infect. Dis. 20,
425–434 (2020).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19684-y
8 NATURE COMMUNICATIONS |         (2020) 11:5838 | https://doi.org/10.1038/s41467-020-19684-y | www.nature.com/naturecommunications
33. Poelmans, J. et al. Longitudinal, in vivo assessment of invasive pulmonary
aspergillosis in mice by computed tomography and magnetic resonance
imaging. Lab. Investig. 96, 692–704 (2016).
34. Vande Velde, G. et al. Longitudinal micro-CT provides biomarkers of lung
disease that can be used to assess the effect of therapy in preclinical mouse
models, and reveal compensatory changes in lung volume. DMM Dis. Model.
Mech. 9, 91–98 (2016).
35. de Langhe, E. et al. Quantification of lung fibrosis and emphysema in mice
using automated micro-computed tomography. PLoS ONE 7, e43123 (2012).
36. Zivcec, M., Safronetz, D., Haddock, E., Feldmann, H. & Ebihara, H. Validation
of assays to monitor immune responses in the Syrian golden hamster
(Mesocricetus auratus). J. Immunol. Methods 368, 24–35 (2011).
37. Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated
gene in human airway epithelial cells and is detected in specific cell subsets
across tissues. Cell 181, 1016.e19–1035.e19 (2020).
38. Onabajo, O. O. et al. Interferons and viruses induce a novel primate-specific
isoform dACE2 and not the SARS-CoV-2 receptor ACE2. Preprint at https://
doi.org/10.1101/2020.07.19.210955 (2020).
39. Mccray, P. B. et al. Lethal infection of K18-hACE2 mice infected with severe
acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
40. Jiang, R. Di et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing
human angiotensin-converting enzyme 2. Cell 182, 50.e8–58.e8 (2020).
41. Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
Nature 583, 830–833 (2020).
42. Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis.
Cell Host Microbe 28, 124.e34–133.e4 (2020).
43. Yang, X. H. et al. Mice transgenic for human angiotensin-converting enzyme 2
provide a model for SARS coronavirus infection. Comp. Med. 57, 450–459
(2007).
44. Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine
efficacy. Science 369, 1603–1607 (2020).
45. Mordstein, M. et al. Lambda interferon renders epithelial cells of the
respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84,
5670–5677 (2010).
46. Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates
protection by neutralizing antibodies. Cell 182, 744.e4–753.e4 (2020).
47. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of
COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol.
20, 363–374 (2020).
48. Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine
profiles in the peripheral blood of SARS-CoV-2 infected patients.
EBioMedicine 55, 102763 (2020).
49. Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The
proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452 (2020).
50. Zhang, T., Wu, Q. & Zhang, Z. Probable pangolin origin of SARS-CoV-2
associated with the COVID-19 outbreak. Curr. Biol. 30, 1346.e2–1351.e2
(2020).
51. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation. Science 367, 1260–1263 (2020).
52. Lau, S.-Y. et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2
junction. Emerg. Microbes Infect. 9, 837–842 (2020).
53. Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1
dependent but a type I, II and III interferon receptor independent mechanism.
PLoS Pathog. 6, 1–14 (2010).
54. Park, C., Li, S., Cha, E. & Schindler, C. Immune response in Stat2 knockout
mice. Immunity 13, 795–804 (2000).
55. Gowen, B. B. et al. Modeling severe fever with thrombocytopenia syndrome
virus infection in golden Syrian hamsters: importance of STAT2 in preventing
disease and effective treatment with favipiravir. J. Virol. 91, e01942-16 (2017).
56. Siddharthan, V. et al. Zika virus infection of adult and fetal STAT2 knock-out
hamsters. Virology 507, 89–95 (2017).
57. Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W. & Levy, D. E.
Constitutive type I interferon modulates homeostatic balance through tonic
signaling. Immunity 36, 166–174 (2012).
58. Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing
macrophage responses during acute SARS-CoV infection. JCI Insight 4,
e123158 (2019).
59. Ochsner, S. A., Pillich, R. T. & McKenna, N. J. Consensus transcriptional
regulatory networks of coronavirus-infected human cells. Sci. Data 7, 314
(2020).
60. Yurdaydin, C. New treatment options for delta virus: is a cure in sight? J. Viral
Hepat. 26, 618–626 (2019).
61. Andreakos, E., Zanoni, I. & Galani, I. E. Lambda interferons come to light:
dual function cytokines mediating antiviral immunity and damage control.
Curr. Opin. Immunol. 56, 67–75 (2019).
62. Prokunina-Olsson, L. et al. COVID-19 and emerging viral infections: the case
for interferon lambda. J. Exp. Med. 217, e20200653 (2020).
63. Major, J. et al. Type I and III interferons disrupt lung epithelial repair during
recovery from viral infection. Science 369, eabc2061 (2020).
64. Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon
viral recognition. Science 369, eabc3545 (2020).
65. Liu, Q., Zhou, Y. H. & Yang, Z. Q. The cytokine storm of severe influenza and
development of immunomodulatory therapy. Cell. Mol. Immunol. 13, 3–10
(2016).
66. Cully, M. Immune status could determine efficacy of COVID-19 therapies.
Nat. Rev. Drug Discov. 19, 431–434 (2020).
67. Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6
signaling in clinic. Immunity 50, 1007–1023 (2019).
68. Portsmore, S., Tran Nguyen, T. N., Beacham, E. & Neelakantan, P.
Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related
sHLH, potential game changer. Br. J. Haematol. https://doi.org/10.1111/
bjh.16966 (2020).
69. Jordan, S. C. et al. Compassionate use of tocilizumab for treatment of SARS-
CoV-2 pneumonia. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa812
(2020).
70. Morillas, J. A. et al. Tocilizumab therapy in five solid and composite tissue
transplant recipients with early ARDS due to SARS-CoV-2. Am. J. Transplant.
https://doi.org/10.1111/ajt.16080 (2020).
71. Foss, F. M. et al. Attenuated novel SARS coronavirus 2 infection in an
allogeneic hematopoietic stem cell transplant patient on ruxolitinib. Clin.
Lymphoma Myeloma Leuk. 20, 720–723 (2020).
72. Koschmieder, S. et al. Favorable COVID-19 course despite significant
comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur.
J. Haematol. 105, 655–658 (2020).
73. Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir
(GS-5734) is mediated by the viral polymerase and the proofreading
exoribonuclease. MBio 9, e00221-18 (2018).
74. White, J. K. et al. XGenome-wide generation and systematic phenotyping of
knockout mice reveals new roles for many genes. Cell 154, 452 (2013).
75. Spiteri, G. et al. First cases of coronavirus disease 2019 (COVID-19) in the
WHO European Region, 24 January to 21 February 2020. Euro Surveill. 25,
2000178 (2020).
76. Vrancken, B. et al. Accounting for population structure reveals ambiguity in
the Zaire Ebolavirus reservoir dynamics. PLoS Negl. Trop. Dis. 14, e0008117
(2020).
77. Conceição-Neto, N. et al. Modular approach to customise sample preparation
procedures for viral metagenomics: a reproducible protocol for virome
analysis. Sci. Rep. 5, 16532–16532 (2015).
78. Conceição-Neto, N., Yinda, K. C., Van Ranst, M. & Matthijnssens, J. NetoVIR:
modular approach to customize sample preparation procedures for viral
metagenomics. Methods Mol. Biol. 1838, 85–95 (2018).
79. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using
real-time quantitative PCR and the 2−ΔΔCT method. Methods 25, 402–408
(2001).
80. Stewart, C. E., Rall, R. E. & Adamson, C. S. Inhibitors of the interferon
response enhance virus replication in vitro. PLoS ONE 9, e112014 (2014).
81. Vandeghinste, B. et al. Iterative CT reconstruction using shearlet-based
regularization. IEEE Trans. Nucl. Sci. 60, 3305–3317 (2013).
82. Berghen, N. et al. Radiosafe micro-computed tomography for longitudinal
evaluation of murine disease models. Sci. Rep. 9, 17598 (2019).
Acknowledgements
We thank Kathleen Van den Eynde, Eef Allegaert, Sarah Cumps, Wilfried Versin,
Caroline Collard, Elke Maas, Jasper Rymenants, Jasmine Paulissen, Nathalie Thys, Céline
Sablon, Catherina Coun, and Madina Rasulova for excellent technical assistance. We
thank Johan Nuyts for support with imaging file processing; Pieter Mollet for support
with the micro-CT installation; Jef Arnout and Annelies Sterckx and Animalia and
Biosafety Departments of KU Leuven for facilitating the studies. We also thank Dr.
Claude Libert for providing the Ifnar1−/− mice and the Wellcome Trust Sanger MGP for
providing the Il28r−/− mutant mouse line. This project has received funding from the
European Union’s Horizon 2020 research and innovation program (No. 101003627 and
No. 733176), funding from BMGF (INV-00636), FWO Flanders (VirEOS project
30981113), the FWO Hercules Foundation, the KU Leuven Rega Foundation, “Internal
Funds KU Leuven” awarded to P.M. (project 3M170314), and the Stichting Antoine Faes.
J.Ma was supported by the China Scholarship Council (CSC), J.M.-C. by a doctoral grant
from HONOURs Marie-Sklodowska-Curie training network (721367), B.V. by a FWO
Flanders SB grant (1S28617N), C.C. by the FWO (1001719N), G.V.V. by KU Leuven
Internal Funds (C24/17/061), K.D. by KU Leuven Internal Funds (C3/19/057 Lab of
Excellence), G.O. and E.M. by KU Leuven Internal Funds (C16/17/010) and by FWO
Flanders, D.D.V. by an FWO SB grant, and B.S. by FWO-EOS project VIREOS. COVID-
19 research in the X.S. and N.C. laboratories is supported by VIB, by a Ghent University
GOA grant, and VIB, UGent and FWO emergency Covid-19 grants.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19684-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5838 | https://doi.org/10.1038/s41467-020-19684-y | www.nature.com/naturecommunications 9
Author contributions
R.B., H.J.T., J.N., and K.D. designed experiments; R.B., S.J.F.K, R.L., V.V., L.L., J.V.W.,
C.D.K., S.S., D.V.L., T.V., X.W., E.M., K.R., D.D.V., B.S., L.B., T.V.B., J. Ma, L. Close,
J.M.-C., B.V., T.W.-B., P.M., and W.C. carried out the experiments; R.B., H.J.T., L.S., S.J.,
J.V.W., D.J., E.M., L.W., B.W., P.M., C.C., G.V.V., Z.W., and K.D. analyzed the data; L.D.,
J.R.-P., J. Matthijnssens, G.S., K.V.L., and G.O. provided advice on the interpretation of
data; R.B., H.J.T., and K.D wrote the original draft with input from co-authors; R.B.,
H.J.T., L.S., J.V.W., C.C., G.V.V., J.N., and K.D. wrote the final draft; R.L., Y.L., and Z.W.
developed the STAT2−/− and IL28R-a−/− hamster strains; K.R., D.D.V., B.S., P.M., R.L.,
Y.L., Z.W., X.S., N.C., V.C., M.V.R., and G.O. provided essential reagents; E.H., D.S., and
P.L. provided and facilitated access to essential infrastructure; H.J.T., J.N., and K.D.
supervised the study; K.D., L. Coelmont, P.L., and J.N. acquired funding; all authors
approved the final manuscript.
Competing interests
D.D.V., B.S., and X.S. are named as inventors on US patent application no. 62/988,610,
entitled “Coronavirus Binders.” D.D.V., B.S., X.S., and N.C. are named as inventors on
US patent application no. 62/991,408, entitled “SARS-CoV-2 Virus Binders.”
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-19684-y.
Correspondence and requests for materials should be addressed to H.J.T., J.N. or K.D.
Peer review information Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
Robbert Boudewijns 1,2,3,22, Hendrik Jan Thibaut 1,3,4,22✉, Suzanne J. F. Kaptein 1,3,22, Rong Li5,22,
Valentijn Vergote 1,6,7, Laura Seldeslachts8, Johan Van Weyenbergh6, Carolien De Keyzer1,2,3,
Lindsey Bervoets1,3, Sapna Sharma 1,2,3, Laurens Liesenborghs 1,2,3, Ji Ma1,2,3, Sander Jansen 1,2,3,
Dominique Van Looveren1,3,4, Thomas Vercruysse1,3,4, Xinyu Wang1,2,3, Dirk Jochmans 1,2,3, Erik Martens9,
Kenny Roose 10,11, Dorien De Vlieger10,11, Bert Schepens10,11, Tina Van Buyten1,3, Sofie Jacobs 1,3, Yanan Liu5,
Joan Martí-Carreras 6,7, Bert Vanmechelen 6,7, Tony Wawina-Bokalanga6,7, Leen Delang 1,3,
Joana Rocha-Pereira1,3, Lotte Coelmont1,2,3, Winston Chiu 1,3, Pieter Leyssen1,3, Elisabeth Heylen 1,3,
Dominique Schols1, Lanjiao Wang1,3, Lila Close6,12, Jelle Matthijnssens 6,12, Marc Van Ranst6,13,14,15,
Veerle Compernolle16,17, Georg Schramm 18,19, Koen Van Laere 18,19, Xavier Saelens 10,11,
Nico Callewaert 10,11, Ghislain Opdenakker 9, Piet Maes 6,7, Birgit Weynand 20,21,
Christopher Cawthorne 18, Greetje Vande Velde 8, Zhongde Wang 5,23, Johan Neyts 1,2,3,23✉ &
Kai Dallmeier 1,2,3,23✉
1Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven Department of Microbiology, Immunology and Transplantation, 3000
Leuven, Belgium. 2Molecular Vaccinology and Vaccine Discovery Group, Leuven, Belgium. 3GVN, Global Virus Network, Baltimore, MD, USA.
4Translational Platform Virology and Chemotherapy, Leuven, Belgium. 5Department of Animal, Dairy, and Veterinary Sciences, Utah State
University, Logan, UT 84322-4815, USA. 6Laboratory of Clinical and Epidemiological Virology, Rega Institute, KU Leuven Department of
Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium. 7Zoonotic Infectious Diseases Unit, Leuven, Belgium. 8KU Leuven
Department of Imaging and Pathology, Biomedical MRI and MoSAIC, 3000 Leuven, Belgium. 9Immunity and Inflammation Research Group,
Immunobiology Unit, Rega Institute, KU Leuven Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium. 10VIB-
UGent Center for Medical Biotechnology, VIB, 9052 Ghent, Belgium. 11Department of Biochemistry and Microbiology, Ghent University, 9052
Ghent, Belgium. 12Laboratory of Viral Metagenomics, Leuven, Belgium. 13KU Leuven Department of Laboratory Medicine, University Hospitals
Leuven, 3000 Leuven, Belgium. 14National Reference Center for Respiratory Pathogens and Enteroviruses, 3000 Leuven, Belgium. 15Leuven
University Vaccinology Center (LUVAC), 3000 Leuven, Belgium. 16Blood Service, Belgian Red Cross Flanders, Mechelen, Belgium. 17Faculty of
Medicine and Health Sciences, Ghent University, Ghent, Belgium. 18KU Leuven Department of Imaging and Pathology, Nuclear Medicine and
Molecular Imaging and MoSAIC, 3000 Leuven, Belgium. 19Division of Nuclear Medicine, University Hospitals Leuven, 3000 Leuven, Belgium. 20KU
Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, 3000 Leuven, Belgium. 21Division of Translational Cell and
Tissue Research, Leuven, Belgium. 22These authors contributed equally: Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, Rong Li.
23These authors jointly supervised this work: Zhongde Wang, Johan Neyts, Kai Dallmeier. ✉email: hendrikjan.thibaut@kuleuven.be; johan.
neyts@kuleuven.be; kai.dallmeier@kuleuven.be
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19684-y
10 NATURE COMMUNICATIONS |         (2020) 11:5838 | https://doi.org/10.1038/s41467-020-19684-y | www.nature.com/naturecommunications
